Lab Sette
Identification of differentially recognized T cell epitopes in the spectrum of Mtb infection
Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
Virus-specific stem cell memory CD8+ T cells may indicate a long-term protection against evolving SARS-CoV-2
Genome-wide characterization of T cell responses to Bordetella pertussis reveals broad reactivity and similar polarization irrespective of childhood vaccination profiles
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses
Circulating T cell-monocyte complexes are markers of immune perturbations
Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions
A systems vaccinology resource to develop and test computational models of immunity
Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
Monovalent SARS-CoV-2 mRNA vaccine does not boost Omicron-specific immune response in diabetic and control pediatric patients
Antigen discovery for next-generation pertussis vaccines using immunoproteomics and transposon directed insertion sequencing
Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination
Corrigendum: Cross-reactive humoral and CD4+ T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population
nteraction of an α-synuclein epitope with HLA-DRB1∗15:01 triggers enteric features in mice reminiscent of prodromal Parkinson’s disease
T cell reactivity to Bordetella pertussis is highly diverse regardless of childhood vaccination
Cross-reactive humoral and CD4+ T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population
T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity
Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to Variants of Concern
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic
IEDB and CEDAR: two sibling databases to serve the global scientific community
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
An update on studies characterizing adaptive immune responses in SARS-CoV-2 infection and COVID-19 vaccination
Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses
Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox
Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
Evaluation of cross-immunity to the Mpox virus due to historic Smallpox vaccination
T cell exhaustion is associated with cognitive status and amyloid accumulation in Alzheimer’s disease
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells
CD4+ T Cell Responses to Toxoplasma gondii Are a Double-Edged Sword
An integrated workflow to assess technical and biological variability of cell population frequencies in human peripheral blood by flow cytometry
A measles virus-based vaccine induces robust chikungunya virus-specific CD4+ T-cell responses in a phase II clinical trial
The megapool approach to characterize adaptive CD4+ and CD8+ T cell responses
A meta-analysis of epitopes in prostate-specific antigens identifies opportunities and knowledge gaps
Identification of cow milk epitopes to characterize and quantify disease-specific T cells in allergic children
Interaction of an α-synuclein epitope with HLA-DRB1∗15:01 triggers enteric features in mice reminiscent of prodromal Parkinson’s disease
Early antiviral CD4 and CD8 T cell responses are associated with upper respiratory tract clearance of SARS-CoV-2
Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination
A prototype-pathogen approach for the development of Flavivirus countermeaseures
A multi-omics systems vaccinology resource to develop and test computational models of immunity
Investigating viral and autoimmune T cell responses associated with post-acute sequelae of COVID-19
A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer
Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant
Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report
PINK1 is a target of T cell responses in Parkinson’s disease
T cell responses in pregnant women who received mRNA-based vaccination to prevent COVID-19 revealed unknown exposure to the natural infection and numerous SARS-CoV-2-specific CD4- CD8- double negative T cells and regulatory T cells
Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection
Pre-existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86
PEPMatch: a tool to identify short peptide sequence matches in large sets of proteins
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
Thioamide analogues of MHC I antigen peptides
Ex vivo assays show human gamma-delta T cells specific for common allergens are Th1-polarized in allergic donors
Mpox-specific immune responses elicited by vaccination or infection in people living with HIV
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
How COVID-19 ‘breakthrough’ infections alter your immune cells
LA JOLLA, CA—New research from scientists at La Jolla Institute for Immunology (LJI) suggests people who received COVID-19 vaccines and then experienced “breakthrough” infections are especially well armed against future SARS-CoV-2 infections.
LJI scientist Alison Tarke honored by Italian government
Tarke established important U.S.-Italy research collaborations amidst the COVID-19 pandemic
T cells tackle new ‘Pirola’ SARS-CoV-2 variant
LJI scientists harness bioinformatics to predict how T cells may adapt to fighting the highly mutated Pirola variant
Asymptomatic infections may underlie recent rise in whooping cough
Surprising insights on pertussis vaccines pave the way for next-gen protection
Family resemblance: How T cells could fight many coronaviruses at once
LJI researchers work to head off future pandemics by uncovering key similarities between SARS-CoV-2 and common cold coronaviruses
LJI Professor Alessandro Sette elected to the American Academy of Microbiology
Sette has led investigations into the T cell response to SARS-CoV-2, tuberculosis, and more
LJI scientists confirm smallpox vaccine also teaches T cells to fight mpox
There’s even more reason to think a vaccine developed against smallpox can help the body fight against mpox (monkeypox virus disease) as well, according to researchers at La Jolla Institute for Immunology (LJI).
LJI scientists reflect on what it means to make the “Highly Cited” list
A record number of LJI researchers have been named to the 2022 list, including two early career scientists
Your body remembers common cold coronaviruses from childhood. How can you get the same immunity to COVID-19?
COVID-19 boosters may lead to a stable antibody and T cell population in years to come
LJI scientists publish first head-to-head comparison of four COVID-19 vaccines
New investigation reveals the strength of T cell, B cell, and antibody responses over time
Scientists uncover new targets for treating Parkinson’s disease
LJI study suggests therapies could stop T cells from attacking brain cells in Parkinson's
Current vaccines teach T cells to fight Omicron
New LJI study shows how the fully vaccinated respond to a range of SARS-CoV-2 variants
¡Felicidades, Alba y Alex!
LJI COVID-19 researchers Alba Grifoni and Alessandro Sette win top honors from the Spanish Society of Immunology
T Cells Might Be Our Bodies’ Best Shot Against Omicron
When a T cell makes up its mind to kill, it does not mess around.
Six LJI scientists named “Highly Cited Researchers”
The international recognition reflects how LJI research is valued by scientific peers
Lungs of COVID-19 survivors teem with virus-fighting ‘memory’ cells
Even elderly survivors show a strong, persistent immune memory
Moderna COVID-19 vaccine spurs lasting immune response
Immune system memory stays strong 6+ months post-vaccination, similar to responses in recovered COVID-19 patients
What you need to know about variants, vaccines, and breakthrough COVID cases
The CDC is reporting every severe breakthrough, but less is known about non-severe cases.
Can we stretch existing Covid vaccines to inoculate more people? Experts are divided
With the global supply of Covid-19 vaccine still woefully inadequate, vaccine makers are scouring the pharmaceutical landscape for partners to ramp up manufacturing
Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants
LJI researchers highlight the importance of T cell cross reactivity in stopping severe COVID-19 cases
In-Depth: San Diego’s most influential COVID-19 researchers
Throughout the pandemic, scientists in San Diego have made big contributions
LJI launches new global cancer immunology resource
National Cancer Institute support brings cancer researchers together to share key findings
In-Depth: La Jolla Institute takes comprehensive look at COVID-19 immunity
Study compares four vaccines and natural immunity
A COVID-fighter’s guide to T cells
New LJI review shows how T cells target more than 1,400 sites on SARS-CoV-2
Had Covid? You May Need Only One Dose of Vaccine, Study Suggests
People who have already been sick with Covid-19 should still be vaccinated, experts say, but they may experience intense side effects even after one dose.
Coronavirus mutations add urgency to vaccination effort as experts warn of long battle ahead
T cells can mount attacks against many SARS-CoV-2 targets—even on new virus variant
New LJI research gives detailed look at vulnerable sites on the novel coronavirus—beyond the receptor binding domain
COVID-19 immunity could be long term
New findings suggest that immune response to COVID-19 may be long-lasting.
Post-infection coronavirus immunity usually robust after 8 months, study shows
Protective immunity against SARS-CoV-2 could last eight months or more
Why declining antibodies don't spell disaster for long-lasting immunity
Covid- 19 – Good news on immunity
After infection or vaccination immunity to the virus may be long lasting
Inside the labs of three leading San Diego scientists
LJI Professors Shane Crotty, Ph.D., Bjoern Peters, Ph.D., and Alessandro Sette, Dr. Biol. Sci., were named “Highly Cited Researchers” this week by Clarivate.
The End of the Pandemic Is Now in Sight
A year of scientific uncertainty is over. Two vaccines look like they will work, and more should follow.
Athlerosclerosis
ATHEROSCLEROSIS Working in collaboration with LJI Professor Klaus Ley, the Sette Lab aims to help develop vaccines that target inflammatory factors as a means to reduce atherosclerotic plaque formation. The researchers have identified several peptides suitable for vaccinating humans. The…
Coronavirus immunity: It’s complicated
The body’s immune system is immensely intricate. A new study released in the UK is causing a stir because of what it says about possible limits to our immunity to COVID-19. Dr. Alessandro Sette talks with The World’s Marco Werman about what the study’s results mean for the possibility of a strong coronavirus vaccine.
Daniela Weiskopf Awarded $1.4 million to Study COVID-19 in Latino Americans
New funding from the National Cancer Institute will let scientists get “whole picture” of the immune response
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
Finding may help explain why people 65 and above face a higher risk of falling critically ill with COVID-19
LJI scientists receive $3.5 million to investigate role of immune cells in Parkinson’s disease
More than 930,000 Americans are living with Parkinson's disease
Forty percent of people with coronavirus infections have no symptoms. Might they be the key to ending the pandemic?
New research suggests that some of us may be partially protected due to past encounters with common cold coronaviruses
Why antibodies may not be the key to beating coronavirus
Worries over waning antibodies may be overblown, as growing evidence shows a role for T cells in the coronavirus immune response.
The Coronavirus Is New, but Your Immune System Might Still Recognize It
Convalescent plasma lowers COVID-19 death risk; exposure to common cold may limit disease severity
The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
